Adaptive Q2 2026: MRD Growth Stalls, Profitability Target Missed

What happened

Adaptive Biotechnologies' second-quarter 2026 results revealed MRD revenue growth slowing to low single digits, missing aggressive street projections and management's own profitability timeline. The net loss swelled as operating expenses outpaced modest gross-profit gains, with the MRD segment still in the red. Management pointed to sluggish clinician uptake and EHR-integration delays, while simultaneously filing a $150 million equity shelf, signaling near-term funding anxiety. Cash reserves dipped below $170 million, raising the specter of dilution before sustained self-funding arrives. The release confirms that competitive pressures and operational inertia are taking a real toll on the once-fast-growing diagnostics franchise.

Implication

While clonoSEQ’s reimbursement moat remains defensible, the investment thesis has shifted from rapid MRD scaling to capital preservation; any upside now hinges on convincing volume acceleration and cost discipline. Investors should track adoption metrics and cash runway closely, as further stumbles could undermine long-term value. The missed profitability milestone erodes confidence that Adaptive can self-fund without substantial dilution, making the risk-reward profile only balanced at current levels. Until management demonstrates consistent execution and a clear line of sight to positive operating cash flow, we see the stock as range-bound and warranting a more cautious posture.

Thesis delta

Slower MRD revenue growth and the failure to achieve MRD profitability by mid-2026 force a downgrade from BUY to HOLD. While the core reimbursement advantage endures, the timeline to self-funding has lengthens, increasing dilution risk and capping near-term upside.